Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Leases (2019 - 2025)

Historic Current Leases for Ptc Therapeutics (PTCT) over the last 7 years, with Q3 2025 value amounting to $11.8 million.

  • Ptc Therapeutics' Current Leases fell 1631.83% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 1631.83%. This contributed to the annual value of $10.4 million for FY2024, which is 2029.69% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Current Leases of $11.8 million as of Q3 2025, which was down 1631.83% from $11.7 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Current Leases high stood at $14.6 million for Q1 2024, and its period low was $7.1 million during Q3 2021.
  • In the last 5 years, Ptc Therapeutics' Current Leases had a median value of $10.2 million in 2023 and averaged $10.3 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Current Leases soared by 7547.85% in 2021, and later plummeted by 2132.86% in 2025.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Current Leases stood at $7.3 million in 2021, then grew by 28.83% to $9.4 million in 2022, then skyrocketed by 38.76% to $13.0 million in 2023, then decreased by 20.3% to $10.4 million in 2024, then rose by 13.96% to $11.8 million in 2025.
  • Its last three reported values are $11.8 million in Q3 2025, $11.7 million for Q2 2025, and $11.5 million during Q1 2025.